OF4949, NEW INHIBITORS OF AMINOPEPTIDASE B V. EFFECT ON THE MURINE IMMUNE SYSTEM
Susumu Sano, Hiroyuki Kuroda, Mitsuhiro Ueno, Yoshie Yoshikawa, Teruya Nakamuraand Akira Obayashi Central Research Laboratories, Takara Shuzo Co., Ltd., 3-4-1 Seta, Otsu, Shiga 520-21, Japan (Received for publication September 3, 1986) OF4949-I inhibited the growth of the solid form of IMC carcinoma and protected against pulmonary metastases of Lewis lung carcinoma. It also augmented the cytostatic activity of mouse peritoneal macrophages, the natural killer activity, and the antibody-dependent cell-mediated cytotoxicity of mousespleen cells. This substance was not cytotoxic to cultured tumor or normal cells even at high concentrations. These results suggest that a cell-mediated immuneresponse stimulated by this compoundmight account for its antitumor activity.
OF4949-I and II are inhibitors of aminopeptidase B from Ehrlich ascites carcinoma (EAC). They were isolated from the culture broth of Penicillium rugulosum OF4949 and identified as novel cyclic peptides containing diphenyl ether as a chromophore.1'^They are selective inhibitors of aminopeptidase B, leucine aminopeptidase, and enkephalin-degrading aminopeptidase.3) These inhibitors enhance the delayed-type hypersensitivity (DTH) of mice to sheep red blood cells (SRBC), and have very low toxicity.^As reported by Umezawaet aL?~^various inhibitors of aminopeptidase enhance the immuneresponse. Amastatin increases the number of antibody-forming cells in mousespleen; bestatin, arphamenines A and B, a-aminoacyl arginine, and diprotins A and B enhance DTHand other cell-mediated immune responses. Bestatin and arphamenines A and B have antitumor activity in animals. So we thought that I and II might enhance immuneresponses directed against tumor cells. Here, we report on the antitumor activity and the immuno-potentiating activity of I. females, 4-6 weeks old), and C57BL/6 mice (males, 8-10 weeks old) were purchased from the Shizuoka Agricultural Cooperative Association for Laboratory Animals, Hamamatsu, Japan. The ICR mice (females, 4-6 weeks old) were from Clea Japan, Inc., Tokyo, Japan. Cell Lines IMCcarcinoma was kindly provided by the Institute of Microbial Chemistry, Tokyo. Wemaintained IMC carcinoma in CDF1mice by ip inoculation every 7 days. Lewis lung carcinoma (3LL), the kind gift of Dr. Shigeru Tsukagoshi of the Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, was maintained by biweekly sc transplantation in C57BL/6 mice.
The cultured cell lines L5178Y (mouse leukemia) and YAC-1(mouse Molony leukemia) were kindly provided by the National Cancer Center Research Institute, Tokyo. C3Hmouse embryonic kidney cells (C3H-2K), the SV40-transformed cell line of C3H-2K (SV-C3H), Fisher rat embryonic APR. 1987 cells (3Y1), the SV40-transformed cell line of 3Y1 (SV-3Y1), NIH mouse embryonic cells (NIH-L1), the 4NQO-transformed cell line of NIH-L1 (L1-4NQO), Swiss mouse embryonic cells (3T3), and Chinese hamster ovary cells (CHO/Pro"") were kindly provided by Dr. Kazukiyo Onodera of the University of Tokyo, Department of Agricultural Chemistry.
Antitumor Effect First, 4 x 106 cells of IMCcarcinoma were implanted sc into the flank of CDF1mice. OF4949-I was given ip daily for 7 days on different schedules.
To test the effect of I on secondary transplanted tumors, 2x lO6 cells of IMCcarcinoma were inoculated into the left hind footpad of CDFXmice. Three days before the inoculation of the second tumor, the first tumor was removed by amputation of the foot. Fourteen days after the inoculation of the first tumor, 105 of the tumor cells were transplanted by ip injection, and I was given ip daily for 7 days from 24 hours after this second inoculation.
Anti-metastatic Activity Lewis lung carcinoma cells (2 x 105 viable cells) were prepared10 and implanted sc in the left hind footpad of BDFi mice. On day 15, the foot bearing the first tumor was surgically amputated. Metastatic pulmonary nodules were counted on day 28. OF4949-X was given ip daily from day 1 to ll.
Antibody Formation
CDFi mice were immunized with 108 SRBCby iv injection, and I was given ip at the same time. Four days later, the numbers of plaque-forming cells (PFC) amongmouse spleen cells were measured by the hemolytic plaque technique12) with SRBCand guinea pig complement.
Cytostatic Assay Tumor-free CDFj mice were given I ip. [3H]TdR uptake with cultured target cells only (cpm) xlOO To examine the influence of I on natural killer (NK) activity, I was injected ip into CDFi or C57BL/6 mice. One to 7 days later, non-adherent mouse spleen cells were prepared and assayed for NKactivity against YAC-1as the target in a 51Cr release assay.14)
To study the effects of I on the antibody-dependent cell-mediated cytotoxicity (ADCC), various doses of I were given ip to CDFi mice daily for 5 days. Twenty-four hours after the last injection, the ADCCactivity of whole spleen cells was assayed with chicken red blood cells (CRBC)as the target by the method of Hinumaet o/. 15) Assay of Colony-forming Units in Culture (CFU-C) Bonemarrowcells of CDFifemale mice were cultured in a-MEM with colony-stimulating factor based on the method of Metcalf16) and Stanley et alu) After 10 days of incubation, CFU-Cwas counted by the method of Ishizuka et alfi Serum induced by lipopolysaccharide (LPS) was used as the colony-stimulating factor. OF4949-I was added at various concentrations at the start of the culture. 
Results

Effects on Murine Transplantable Tumors
The antitumor effects of I against the solid form of IMC carcinoma were examined. OF4949-I inhibited the growth of the tumors by ip injection from days 0 to 6 or from days 7 to 13 at doses of 0.5 or 5 mg/kg/day, but not by treatment from days -7 to -1 (Table 1) (Table 2) . To elucidate the antitumor mechanismof I, we examined cell-growth inhibition by I and II using cultured neoplastic or normal cell lines (L5178Y, YAC-1, SV-C3H, SV-3Y1, L1-4NQO, CHO/Pro", 3T3, C3H-2K, 3Y1, and NIH-L1). In contrast to the results in vivo, I did not inhibit growth of any of the cultured cells tested at the concentration of 100^g/ml. These results indicated that the antitumor effects of I were not due to direct cytotoxicity.
Effects on Formation of Antibodies to SRBC The effects of I and II on antibody formation to SRBCwere tested by the hemolytic plaque technique. Administration of I increased the number of antibody-forming cells by about 30% at doses of from 0.05 to 5.0 mg/kg, but the increases were not statistically significant.
Effect on Macrophage, NK and ADCCActivity
We examined the effects of I on the cytostatic activity of peritoneal macrophages. The intraperitoneal administration of I augmented the cytostatic activity of PC in doses of 0.05 to 5.0 mg/kg. The APR. 1987 cell fraction of PC from I-treated mice that adhered to plastic was very active, but [3H]TdR incorporation into tumor cells was almost not inhibited at all by the I-treated non-adherent cell fraction. Furthermore, the activity of whole PC treated with I was not eliminated by treatment with anti-Thy 1.2 serum and complement. These results suggested that I augmented the cytostatic activity of PC through the stimulation of macrophages. The effect on the cytostatic activity of PC from mice bearing IMCcarcinoma was next examined. Student's t-test compared with control (control, n=6 ; experimental, n= 3). E/T : Effector/target ratio.
Administration of I increased the cytostatic activity of the PC even from tumor-bearing mice (Table 3) . To examine the effects on NKactivity, the cytotoxic activity of mousespleen cells against YAC-1 cells was measured daily for 7 days after a single injection of I. The NKactivity peaked at 3 days after ip injection of I. Administration of from 0.5 to 5.0 mg/kg of I caused a 1.5-to 2.5-fold increase compared with untreated animals at that time ( Table 4) .
The effect of I on ADCCactivity against SRBCwas next studied. ADCCactivity was much enhanced by administration of I at doses of from 0.05 to 5.0 mg/kg/day (Table 5) .
Effect on CFU-CProduction in Culture of Mouse Bone Marrow Cells The in vitro effect of I on the generation of granulocyte-macrophage progenitor cells in bone marrow was studied. The addition to the culture of from 0.001 to 0.01^g/ml of I with LPS-induced colony-stimulating factor increased the numbers of CFU-C by about 50%. Without added colonystimulating factor, colony formation did not occur in bone-marrow cells in either the control of Itreated cultures.
Discussion
In this study, we found that OF4949-I had antitumor activity against subcutaneous solid IMC carcinoma and was effective in protecting against pulmonary metastases of Lewis lung carcinoma.
To elucidate the antitumor mechanismsof this compound,weexamined the effect of I on the growth of cultured cells and on the mouseimmunesystem. OF4949-I was not cytotoxic to any of the cells tested. In experiments that tested its effect on immuneresponses, I increased the numbers of PFC to SRBCslightly, suggesting that humoral immunity was not much influenced. On the other hand, I enhances the DTHresponse,0 the cytostatic activity of peritoneal macrophages, and NK, and ADCC activities in mouse spleen cells. These results suggest that the antitumor effect of I could be partly explained by the augmentation of cellular immuno-response mediated by macrophages, NKcells, or both. When we compared the enhencing of macrophages, NKand ADCC, by I and by bestatin under the sameexperimental conditions, significant defferences were not found.
The increasing evidence that macrophages and NKcells are important in the host's defence against neoplasia has stimulated interest in agents that can activate these cells. Several natural products of small molecular weight and their derivatives, such as bestatin,5) forphenicinol,18) FK 156, FK 565,19) tuftsin,205 and myroridin-K21) can stimulate macrophage or NKactivity. These immunity-enhancing Spleen cells of CDF], or C57BL/6 mice were cultured in RPMI 1640 medium with I with or without Con A (5^g/ml) or LPS (2^g/ml) for 3 days. Eighteen hours before being harvested, each culture was labeled with [3H]TdR, and its incorporation into the cells was measured. APR. 1987 agents of small molecular weight, including I, may become clinically useful immuno-potentiators, because they have no antigenicity and low toxicity. Moreover, some of them enhance the production of CFU-Cof bone-marrow stem cells of mice by stimuli in serum from LPS-treated mice.5»18) In our experiment with in vitro culture of bone marrowcells, treatment with I also increased CFU-Gformation. In a preliminary experiment, the addition of I at doses from 0.1 to 100^g/ml enhanced incorporation of [3H]thymidine into lymphocytes by about 50%, but did not influence the mitogenicity of concanavalin A (Con A) or LPS (Table 6 ). OF4949-I may be interesting and useful in both immunology and enzymology.3)
